ArticleCancer immunology, immunotherapy : CII2025
Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer.
Article in Cancer immunology, immunotherapy : CII, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic Targeting of VEGFR-2, PD-L1, and EGFR-MET Pathways in Non-Small Cell Lung Cancer: Clinical Progress with Ramucirumab, Atezolizumab, and Amivantamab.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough atezolizumab has demonstrated efficacy in advanced non-small-cell lung cancer (NSCLC), antidrug antibody (ADA) may reduce its effectiveness by lowering drug exposure. We explored the association between ADA levels and clinical outcomes.
methodsWe retrospectively analyzed 86 patients with advanced NSCLC who received atezolizumab monotherapy (1200 mg every 3 weeks) between August 2018 and September 2022 at Samsung Medical Center, Seoul, Korea. Blood samples were collected prior to the first and second doses (baseline and week 3). ADA levels were measured by ELISA and correlated with plasma atezolizumab concentrations and clinical outcomes using Kaplan-Meier estimates and Cox proportional hazards models.
resultsAll 86 patients received atezolizumab as a second-line or later treatment (second-line, n = 65; third-line, n = 12; ≥ fourth-line, n = 9). Patients (median age [IQR], 67 [61-73] years; 73 [84.9%] male) showed significantly elevated ADA levels three weeks after treatment (median [IQR] 0 [0-0] vs. 530.3 [146.9-3050.5] ng/mL; p < 0.001). Strong ADA levels (≥ 1000 ng/mL) were observed in 32 (37.2%) patients and were associated with shorter PFS (HR = 1.86, 95% CI: 1.15-3.02, p = 0.010) and OS (HR = 1.92, 95% CI: 1.14-3.23, p = 0.013). Furthermore, patients with high ADA levels exhibited lower atezolizumab concentrations and reduced response rates compared to those with low ADA levels. Importantly, high ADA levels independently predicted poor prognosis in a multivariable analysis adjusted for clinical variables.
conclusionsHigh ADA levels were linked to lower atezolizumab exposure and worse outcomes. ADA monitoring may help predict prognosis and guide immunotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.